US adults interested in Rx insomnia drugs
According to a recent national study by Guideline Inc, a US provider of custom business research and analysis, consumers are looking for both prescription medications and innovative sleep aids for relief of their insomnia.
When asked what new products they were interested in using to help them sleep, 42% of those with symptoms of insomnia were interested in a prescription medication for their sleeplessness. Yet notably, 64% of those suffering from sleep difficulties said they would pay 5% or more for a hotel room if it promoted sleep.
While it is no secret that most Americans have less than the recommended amount of sleep, of the 800 US adults surveyed on-line by Guideline, 76% of them reported having sleep difficulties.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze